Efficacy and safety of anlotinib combined with anthracycline and ifosfamide followed by anlotinib maintenance in advanced soft tissue sarcoma: A single-arm, phase 2 trial

被引：0
|
作者：
Liu, Zengjun
Liu, Mengyao
Xu, Jing
Hu, Wenyu
Zhu, Dongyuan
Tao, Rongjie
Xu, Ni
Zhang, Hui
Li, Minghuan
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Shandong, Peoples R China
[3] Shandong Canc Hosp & Inst, Rare Tumors Dept, Jinan, Peoples R China
[4] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[5] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol & Radiol, Jinan, Shandong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11553
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns
    Cai, Meng
    Zhu, Jie
    Zhou, Guangxin
    COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE, 2022, 2022
  • [42] Efficacy of anlotinib in advanced soft tissue sarcoma by prior lines of therapy, age and dose modification
    Yao, Y.
    Chi, Y.
    Fang, Z.
    Wang, S.
    Huang, G.
    Cai, Q.
    Shang, G.
    Wang, G.
    Qu, G.
    Wu, Q.
    Jiang, Y.
    Song, J.
    Chen, J.
    Zhu, X.
    Cai, Z.
    Bai, C.
    Lu, Y.
    Yu, Z.
    Shen, J.
    Cai, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] Efficacy of anlotinib in advanced soft tissue sarcoma by age, gender, and ECOG performance status.
    Fang, Zhiwei
    Yao, Yang
    Cai, Jianqiang
    Chi, Yihebali
    Wang, Shusen
    Huang, Gang
    Cai, Qiqing
    Shang, Guanning
    Wang, Guowen
    Qu, Guofan
    Wu, Qiong
    Jiang, Yu
    Song, Jianmin
    Chen, Jing
    Cai, Zhengdong
    Zhu, Xia
    Bai, Chunmei
    Lu, Yongkui
    Yu, Zhihua
    Shen, Jingnan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced soft tissue sarcoma: A single-arm phase
    Luo, Z.
    Liu, X.
    Zhang, X.
    He, X.
    Zhang, S.
    Yan, W.
    Chen, Y.
    Wang, C.
    Xu, Y.
    Yu, L.
    Wang, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1401 - S1401
  • [45] Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study
    Chen, L. K.
    Chen, J.
    Li, M. C.
    Yu, H.
    Zhang, B. S.
    Hou, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S48 - S49
  • [46] Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial
    He, Zhen
    Yang, Xiuli
    Ma, Tianjiang
    Yang, Qiumin
    Zhang, Chenghui
    Chen, Yunfang
    Wang, Pengyuan
    D'Incecco, Armida
    Metro, Giulio
    Uematsu, Shugo
    Wang, Qiming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (08) : 1657 - +
  • [47] Evaluation of hypertension and hand-foot syndrome as markers of anlotinib efficacy in advanced soft tissue sarcoma
    Fang, Z.
    Chi, Y.
    Yao, Y.
    Wang, S.
    Huang, G.
    Cai, Q.
    Shang, G.
    Wang, G.
    Qu, G.
    Wu, Q.
    Jiang, Y.
    Song, J.
    Chen, J.
    Zhu, X.
    Cai, Z.
    Bai, C.
    Lu, Y.
    Yu, Z.
    Shen, J.
    Cai, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 587 - 587
  • [48] A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC
    Xiong, J.
    Li, J.
    Deng, J.
    Zhang, W.
    Wang, H.
    Zeng, L.
    Shi, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S675 - S676
  • [49] Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial
    Li, Huihui
    Tan, Qiaorui
    Sun, Shujuan
    Zhou, Dongdong
    Yu, Bo
    Su, Mu
    Li, Baojiang
    Fang, Shu
    Qiang, Ling
    Ren, Guohua
    Bu, Bing
    Yin, Sha
    Man, Xiaochu
    Qiu, Pengfei
    Wang, Xinzhao
    Li, Chao
    Cao, Fangli
    Shao, Qian
    Han, Dali
    Song, Lihua
    Fan, Bingjie
    Zhang, Baoxuan
    Xu, Liang
    Zhao, Xianguang
    Liao, Yuqian
    Xie, Xuemei
    Liu, Lanping
    CANCER RESEARCH, 2023, 83 (05)
  • [50] Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
    Chen, Yueyun
    Ding, Zhen-Yu
    Yuan, Yong
    Yang, Yu-Shang
    Lin, Zhen
    Tian, Jiangfang
    Liu, Ting
    Yue, Zheng
    Shi, Hua-Shan
    Hu, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 352 - 352
12345